Cargando…

Mast cell marker gene signature in head and neck squamous cell carcinoma

BACKGROUND: Mast cells can reshape the tumour immune microenvironment and greatly affect tumour occurrence and development. However, mast cell gene prognostic and predictive value in head and neck squamous cell carcinoma (HNSCC) remains unclear. This study was conducted to identify and establish a p...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Zhimou, Tang, Bingjie, Chen, Lin, Lei, Wenbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128261/
https://www.ncbi.nlm.nih.gov/pubmed/35610596
http://dx.doi.org/10.1186/s12885-022-09673-3
_version_ 1784712527325691904
author Cai, Zhimou
Tang, Bingjie
Chen, Lin
Lei, Wenbin
author_facet Cai, Zhimou
Tang, Bingjie
Chen, Lin
Lei, Wenbin
author_sort Cai, Zhimou
collection PubMed
description BACKGROUND: Mast cells can reshape the tumour immune microenvironment and greatly affect tumour occurrence and development. However, mast cell gene prognostic and predictive value in head and neck squamous cell carcinoma (HNSCC) remains unclear. This study was conducted to identify and establish a prognostic mast cell gene signature (MCS) for assessing the prognosis and immunotherapy response of patients with HNSCC. METHODS: Mast cell marker genes in HNSCC were identified using single-cell RNA sequencing analysis. A dataset from The Cancer Genome Atlas was divided into a training cohort to construct the MCS model and a testing cohort to validate the model. Fluorescence in-situ hybridisation was used to evaluate the MCS model gene expression in tissue sections from patients with HNSCC who had been treated with programmed cell death-1 inhibitors and further validate the MCS. RESULTS: A prognostic MCS comprising nine genes (KIT, RAB32, CATSPER1, SMYD3, LINC00996, SOCS1, AP2M1, LAT, and HSP90B1) was generated by comprehensively analysing clinical features and 47 mast cell-related genes. The MCS effectively distinguished survival outcomes across the training, testing, and entire cohorts as an independent prognostic factor. Furthermore, we identified patients with favourable immune cell infiltration status and immunotherapy responses. Fluorescence in-situ hybridisation supported the MCS immunotherapy response of patients with HNSCC prediction, showing increased high-risk gene expression and reduced low-risk gene expression in immunotherapy-insensitive patients. CONCLUSIONS: Our MCS provides insight into the roles of mast cells in HNSCC prognosis and may have applications as an immunotherapy response predictive indicator in patients with HNSCC and a reference for immunotherapy decision-making. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-09673-3.
format Online
Article
Text
id pubmed-9128261
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91282612022-05-25 Mast cell marker gene signature in head and neck squamous cell carcinoma Cai, Zhimou Tang, Bingjie Chen, Lin Lei, Wenbin BMC Cancer Research BACKGROUND: Mast cells can reshape the tumour immune microenvironment and greatly affect tumour occurrence and development. However, mast cell gene prognostic and predictive value in head and neck squamous cell carcinoma (HNSCC) remains unclear. This study was conducted to identify and establish a prognostic mast cell gene signature (MCS) for assessing the prognosis and immunotherapy response of patients with HNSCC. METHODS: Mast cell marker genes in HNSCC were identified using single-cell RNA sequencing analysis. A dataset from The Cancer Genome Atlas was divided into a training cohort to construct the MCS model and a testing cohort to validate the model. Fluorescence in-situ hybridisation was used to evaluate the MCS model gene expression in tissue sections from patients with HNSCC who had been treated with programmed cell death-1 inhibitors and further validate the MCS. RESULTS: A prognostic MCS comprising nine genes (KIT, RAB32, CATSPER1, SMYD3, LINC00996, SOCS1, AP2M1, LAT, and HSP90B1) was generated by comprehensively analysing clinical features and 47 mast cell-related genes. The MCS effectively distinguished survival outcomes across the training, testing, and entire cohorts as an independent prognostic factor. Furthermore, we identified patients with favourable immune cell infiltration status and immunotherapy responses. Fluorescence in-situ hybridisation supported the MCS immunotherapy response of patients with HNSCC prediction, showing increased high-risk gene expression and reduced low-risk gene expression in immunotherapy-insensitive patients. CONCLUSIONS: Our MCS provides insight into the roles of mast cells in HNSCC prognosis and may have applications as an immunotherapy response predictive indicator in patients with HNSCC and a reference for immunotherapy decision-making. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-09673-3. BioMed Central 2022-05-24 /pmc/articles/PMC9128261/ /pubmed/35610596 http://dx.doi.org/10.1186/s12885-022-09673-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Cai, Zhimou
Tang, Bingjie
Chen, Lin
Lei, Wenbin
Mast cell marker gene signature in head and neck squamous cell carcinoma
title Mast cell marker gene signature in head and neck squamous cell carcinoma
title_full Mast cell marker gene signature in head and neck squamous cell carcinoma
title_fullStr Mast cell marker gene signature in head and neck squamous cell carcinoma
title_full_unstemmed Mast cell marker gene signature in head and neck squamous cell carcinoma
title_short Mast cell marker gene signature in head and neck squamous cell carcinoma
title_sort mast cell marker gene signature in head and neck squamous cell carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128261/
https://www.ncbi.nlm.nih.gov/pubmed/35610596
http://dx.doi.org/10.1186/s12885-022-09673-3
work_keys_str_mv AT caizhimou mastcellmarkergenesignatureinheadandnecksquamouscellcarcinoma
AT tangbingjie mastcellmarkergenesignatureinheadandnecksquamouscellcarcinoma
AT chenlin mastcellmarkergenesignatureinheadandnecksquamouscellcarcinoma
AT leiwenbin mastcellmarkergenesignatureinheadandnecksquamouscellcarcinoma